Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2008 Oct;69(5):381–411. doi: 10.1016/j.curtheres.2008.10.004

Kanglaite injection plus chemotherapy versus chemotherapy alone for non-small cell lung cancer patients: A systematic review and meta-analysis

Xuemei Liu 1, Feng Xu 2, Gang Wang 3, Xiang Diao 4, Youping Li 1,a
PMCID: PMC3969920  PMID: 24692815

Abstract

Background: Kanglaite (KLT) is a botanically sourced, molecularly targeted agent that is prepared as a microemulsion for IV use. The active substance is extracted from the herb Semen coicis.

Objective: The aim of this study was to evaluate the effectiveness and tolerability of KLT injection in patients with primary non-small cell lung cancer (NSCLC).

Methods: We electronically searched the literature of the China National Knowledge Infrastructure (Chinese language, 1979-March 2008), CBMdisc (Chinese, 1978-March 2008), The Cochrane Library (English, Issue 4, 2007), MEDLINE (English, 1966-March 2008), and EMBASE (English, 1984-March 2008), and manually searched 20 Chinese-language oncology journals to identify randomized controlled trials (RCTs) of KLT injection plus chemotherapy versus chemotherapy alone, regardless of their having been published or not, blinding, duration of treatment, or duration of follow-up. The quality of the included trials was assessed using the method recommended by The Cochrane Collaboration. The studies were assigned to 1 of the following 3 categories: A = all quality criteria met, low risk of bias; B = ≥1 of the quality criteria only partially met, moderate risk of bias; or C = ≥1 of the quality criteria not met, high risk of bias. If heterogeneity existed among subgroups, then overall results were calculated based on a random-effects model; otherwise, a fixed-effects model was used.

Results: Electronic database searches yielded 596 citations. A title review eliminated 377 manuscripts; 219 citations were marked for further evaluation. Finally, we identified 26 trials that met the inclusion and exclusion criteria. The 26 RCTs included in this meta-analysis included 2209 patients with NSCLC; no study was graded A, 9 were graded B, and 17 were graded C. The sample size of each trial varied from 40 to 305 patients; none of the trials had precalculated sample sizes. Pooled analyses performed using both fixed- and random-effects models revealed that compared with chemotherapy alone, KLT injection plus chemotherapy improved the response rate (relative risk [RR], 1.34; 95% CI, 1.19–1.51 and RR, 1.35; 95% CI, 1.20–1.51, respectively) and quality of life as measured by an increase ≥10 points in the Karnofsky Performance Status score (RR, 2.05; 95% CI, 1.60–2.64). KLT injection plus chemotherapy was associated with improvement in the symptoms of cough, dyspnea, chest pain, fatigue, and anorexia. KLT injection plus chemotherapy was also associated with significant reduction in the incidence of the following adverse events (AEs) based on the fixed and random effects models, respectively: grade II to IV leukopenia (RR, 0.29; 95% CI, 0.22–0.39 and RR, 0.33; 95% CI, 0.22–0.48), anemia (RR, 0.54; 95% CI, 0.42–0.70 and RR, 0.55; 95% CI, 0.40–0.76), thrombocytopenia (RR, 0.39; 95% CI, 0.21–0.71 and RR, 0.40; 95% CI, 0.21–0.78), nausea and vomiting (RR, 0.44; 95% CI, 0.34–0.57 and RR, 0.44; 95% CI, 0.35–0.57), phlebitis (RR, 3.44; 95% Cl, 1.30–9.15 and RR, 3.38; 95% CI, 1.28–8.89), and hepatic dysfunction (RR, 0.44; 95% CI, 0.15–1.35 and RR, 0.44; 95% CI, 0.24–0.81).

Conclusion: This meta-analysis found that KLT injection in combination with chemotherapy was associated with improved response rate, quality of life, and symptoms, and a reduced incidence of AEs compared with chemotherapy alone in patients with NSCLC. These findings should be viewed with caution because of the low quality of the included trials.

Key Words: kanglaite injection, non-small cell lung cancer, systematic review

Full Text

The Full Text of this article is available as a PDF (1.7 MB).

References

  • 1.Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest. 2006;130:1211–1219. doi: 10.1378/chest.130.4.1211. [DOI] [PubMed] [Google Scholar]
  • 2.An introduction to kanglaite injection. http://www.kanglaite.com Accessed June 27, 2007.
  • 3.Nie LG, Pan ZB, Xu S. Effects of extracts of Semen coicis on telomerase of squamous lung cancer cells. Chin J Clin Pharmacol Ther. 2003;8:419–421. [Google Scholar]
  • 4.Yang H, Wang X, Linlin Y, Shu Z. Effects of kanglaite injection on reversing multiple drug resistance (MDR) of tumor cells. http://www.kanglaite.com Accessed June 27, 2007.
  • 5.Hu Y, Liang H, Gong WK. The effect of kanglaite injection (KLT) on the proliferation and telomerase activity of rat mesangial cells. Zhongguo Zhong Yao Za Zhi. 2005;30:450–453. [PubMed] [Google Scholar]
  • 6.Jiang XL, Zhang Liang, Xu ZY, Goo CH. Effect of kanglaite injection on angiogenesis. http://www.kanglaite.com Accessed June 27, 2007.
  • 7.Liu XM, Zhang MM, Li J, Qiu M. Chinese herbs for symptom palliation in patients with lung cancer. Cochrane Database Sys Rev. 2004;2:CD004698. [Google Scholar]
  • 8.Department of Medical Administration of Ministry of Health of the People's Republic of China . Main measurement indexes and statistical methods in normal cancer in China. Beijing. Beijing Medical University and China Union Medical University Press; China: 1991. Guideline of normal cancer diagnosis and treatment in China. 9th Branch; pp. 11–15. [Google Scholar]
  • 9.Park JO, Lee SI, Song SY. Measuring response in solid tumors: Comparison of RECIST and WHO response criteria. Jpn J Clin Oncol. 2003;33:533–537. doi: 10.1093/jjco/hyg093. [DOI] [PubMed] [Google Scholar]
  • 10.Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  • 11.Alderson P, Green S, Higgins JP, editors. Cochrane Reviewers' Handbook 4.2.2 [updated December 2003] John Wiley & Sons, Ltd; Chichester, UK: 2004. (The Cochrane Library, Issue 1). [Google Scholar]
  • 12.Piao BK, Lin HS, Li PW. Summary of phase III clinical trial of kanglaite injection in the treatment of primary bronchogenic pulmonary carcinoma. http://www.kanglaite.com Accessed June 27, 2007.
  • 13.Chu DT, Wang JW, Liu SX. A phase III clinical study of kanglaite injection combined with chemotherapy (PVM Scheme) in the treatment of non-small cell lung cancer (NSCLC) http://www.kanglaite.com Accessed June 27, 2007.
  • 14.Li SW, Wang Y. Clinical study of Kanglaite combined with chemotherapy for non-small cell lung cancer patients. Tumor. 2002;22:84. [Google Scholar]
  • 15.Yang SJ, Yao YM, Li YF. Clinical observation of Kanglaite injection combined with chemotherapy for non-small cell lung cancer patients. Chin J Integrated Traditional Western Med. 2003;23:629. [PubMed] [Google Scholar]
  • 16.Chen YZ, Li PP, Yan LF. Effective observation of Kanglaite injection plus NVB and DDP regimen for non-small cell lung cancer patients. Chin J Integrated Traditional Western Med. 2003;23:629–630. [Google Scholar]
  • 17.Tang JH. Clinical study of Kanglaite injection combined with HEP regimen for advanced non-small cell lung cancer patients. Tumor. 2002;22:83. [Google Scholar]
  • 18.Xie XD, Zheng ZD, Gao YL. A random control study: Effect of Kanglaite on life quality of patient with lung cancer in advanced stage. Chin J Clin Rehabilitation. 2003;7:672–673. [Google Scholar]
  • 19.Liu JX, Liao ML, Yan DJ, Zhou JY. Kanglaite injection for the treatment of primary lung cancer: A phase II clinical trial. Traditional Chin Drug Res Clin Pharmacol. 1995;6:17–22. [Google Scholar]
  • 20.Lin YH, Wang F, Chen P, Zhang JL. Combination of Kanglaite injection and CAP regimen chemotherapy in treatment of late non-small cell lung cancer. J Qilu Oncol. 2004;11:647–649. [Google Scholar]
  • 21.Lian ZP, Lu YX, Hou EC, Wang X. Combination of GP regimen and Kanglaite in the treatment of advanced non-small cell lung cancer. Chin J Lung Cancer. 2006;9:74–77. doi: 10.3779/j.issn.1009-3419.2006.01.19. [DOI] [PubMed] [Google Scholar]
  • 22.Deng SG, Wen SG, Wen SB, Chen AL. Clinical observation of Kanglaite injection combined with Gemzar and carboplatin for median and advanced non-small cell lung cancer patients. Zhejiang Practical Med. 2006;11:234–236. [Google Scholar]
  • 23.Lu CD. Kanglaite injection combined with chemotherapy for advanced non-small cell lung cancer patients. J Modern Oncol. 2006;14:964–965. [Google Scholar]
  • 24.Lv XY, Zhang YQ, Li QS. Clinical study on quality of life for chemotherapy combined with kanglaite in non-small cell lung cancer. J Clin Pulmonary Med. 2004;9:342–343. [Google Scholar]
  • 25.Wu RL, Ou DB, Pan XJ. Clinical observation of Kanglaite injection combined with NVB and DDP for median and advanced non-small cell lung cancer patients. Shaanxi Oncol Med. 2002;10:201. [Google Scholar]
  • 26.Wu XH, Hua D, Sha LJ, Wu LL. Kanglaite injection combined with MVP regimen for non-small cell lung cancer patients. J Qilu Oncol. 2001;8:657–658. [Google Scholar]
  • 27.Huang JY, Gao P, Wang XQ. Clinical observation of Kanglaite injection combined with EP regimen for advanced non-small cell lung cancer patients. Tumor. 2001;21:392. [Google Scholar]
  • 28.Li ZG, Hu HY, Zhang JS. Observation on efficacy Kanglaite injection combined with chemotherapy in treating non-small cell lung cancer in aged patients. Chin J Cancer Prev Treat. 2003;10:405–406. [Google Scholar]
  • 29.Li ZH, Lv JF, Zhou LZ. Clinical study of combined Kanglaite injection with chemotherapy in treatment of NSCLC. Chin J Cancer Prev Treat. 2005;12:1339–1340. [Google Scholar]
  • 30.Liu YL, Sun XJ, Zhang J, Yang DC. Clinical observation of Kanglaite combined with CEP for non-small cell lung cancer patients. Chin J Cancer Prev Treat. 2003;10:895. [Google Scholar]
  • 31.Chen ZP. Clinical study of Kanglaite injection combined with chemotherapy for 30 advanced lung cancer patients. J Zhejiang College TCM. 1999;23:35. [Google Scholar]
  • 32.Song JL, Zhong LP, Liu ZW. Effect of combined therapy of Kanglaite on quality of life of middle-old aged patients with advanced non-small cell lung cancer. Chin J Clin Rehabilitation. 2002;6:1160–1161. [Google Scholar]
  • 33.Wang ZX, Zhang ZG. Therapeutic effect of Kanglaite injection combined with chemotherapy on advanced non-small cell lung cancer. Hebei Med J. 2007;29:47–48. [Google Scholar]
  • 34.An HJ, Yuan JZ. Clinical observation of Kanglaite combined with NC improve NSCLC of agedness. Chin J Practical Chin Modern Med. 2005;18:1205–1206. [Google Scholar]
  • 35.Ju HB, Chen XJ, Wang BQ. Clinical effect of Kanglaite plus PVM versus simple PVM for non-small cell lung cancer patients. J Pract Oncol. 2000;15:56–57. [Google Scholar]
  • 36.Zhong YH, Liu H, Chen M. Clinical observation of Kanglaite combined with NIC for non-small cell lung cancer patients. Shaanxi Oncol Med. 2001;9:288. [Google Scholar]
  • 37.Wang YL, Li DM, Xu H. Combination of Kanglaite injection and chemotherapy for treatment of advanced non-small cell lung cancer. Oncol Prog. 2005;3:273–275. [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES